Introduction
Biological therapies represent a fundamental step in the management of several chronic and debilitating immunemediated inflammatory diseases, including inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis and psoriatic arthritis (PsA) [1] [2] [3] .
Infliximab (brand name Remicade Ò ; Janssen Biotech, Inc., USA) [4] is a human-murine chimeric monoclonal antibody directed against tumor necrosis factor alpha (TNF-a) that has shown distinct efficacy in patients suffering from Crohn's disease (CD) and ulcerative colitis (UC) [3] . Early treatment with infliximab has been proven to induce clinical remission and to modify disease progression [5] , dramatically improving the quality of life of IBD patients, and infliximab is progressively becoming a relevant drug in these patients' care [6, 7] . Indeed, the advent of biological therapy for IBD has provided more effective control of underlying diseases and sustained amelioration of disease activity, compared with the prebiological era when only anti-inflammatory and immunosuppressant drugs were available [8] . Although the importance of potentially improved clinical outcome cannot be overstated, these efficacious treatments for IBD are not without a high cost [9] .
In fact, the development of biological drugs and the manufacturing processes are rather complex, which increases the cost of these therapies, making them progressively less sustainable in long-term treatment. Many reference biologicals have reached, or are about to reach, patent expiry. As a result, the production of biosimilar drugs is raising considerable interest, as these drugs could potentially reduce the financial burden of the therapy and extend therapeutic alternatives. CT-P13 (Remsima Ò , Celltrion, South Korea, and Inflectra Ò , Hospira, USA) [10, 11] was the first infliximab biosimilar to be approved in several countries with the same therapeutic indications as its originator infliximab {September 2013, approval given by the European Medicines Agency (EMA), http://www.ema. europa.eu [11] ; April 2016, approval given by the US Food and Drug Administration (FDA) (http://www.fda.gov) [12] }. The approval of a biosimilar drug has to follow a strict regulatory pathway, which is slightly different between the USA and EU. In both cases, extensive physicochemical and structural analyses and in vitro functional tests to investigate quality issues (manufacturing process, comparability exercise vs. the originator, analytical methods, physicochemical characterization, biological activity and purity) and non-clinical issues (pharmatoxicological assessment) must be done. In addition, clinical studies are needed to test clinical issues (pharmacokinetic, pharmacodynamics and efficacy) and clinical safety issues (pharmacovigilance and immunogenicity). The clinical studies that addressed the equivalence of CT-P13 to its originator in terms of efficacy and safety were one equivalence trial conducted in patients with RA (PLANETRA: Program evaLuating the Autoimmune disease iNvEstigational drug cT-p13 in RA patients) [13] and a pharmacokinetic study on patients with AS (PLANETAS: Program evaLuating the Autoimmune disease iNvEstigational drug cT-p13 in SA patients) [14] . These two trials [13, 14] demonstrated the equivalence in terms of efficacy and pharmacokinetics between infliximab and its biosimilar CT-P13 and reported similar safety profiles for the two drugs.
In this review, we analyze the data from available clinical trials that recently investigated the validity of indication extrapolation of CT-P13 for the treatment of IBD in naïve patients and in patients who switched from its originator infliximab, focusing on clinical efficacy, safety and immunogenicity, and, therefore, compare the results observed in the PLANETRA and PLANETAS studies.
Methods

Literature Search
A detailed literature search was developed a priori to identify articles that reported the findings from clinical studies that involved the use of the infliximab biosimilar. Key words and subject terms included the following: 
Study Selection
Two independent reviewers (MR and SS) reviewed the studies identified with the above strategy. Eligibility was determined by review of the title and abstract and then by full article review. A study was included if it (1) reported findings from a clinical study of IBD patients treated with infliximab biosimilar and (2) included more than five patients.
The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.
Results
We retrieved 139 articles on the current literature, and of those, 11 studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were eligible for our analysis. The data retrieved from the 11 studies included a total of 570 patients [15] [16] [17] [18] [19] [20] [22] [23] [24] [25] suffering from CD (294 patients switched from infliximab to its biosimilar and 276 patients naïve to treatment with anti-TNF monoclonal antibody therapy), 435 patients suffering from UC [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] (127 patients switched and 308 patients naïve) and two unclassified IBD patients (switched), for a total of 1007 IBD patients treated with CT-P13. Selection of the included studies is detailed in Fig. 1 .
Efficacy
Data regarding the efficacy analysis are summarized in Table 1 .
Overall, efficacy was assessed at week 6-8 in three of the 11 studies, at week 14-16 in seven studies, at week 24 in one study and at week 30 in three studies.
Three studies included patients that switched from an anti-TNF-a monoclonal antibody to CT-P13 [15, 24, 25] , and eight studies reported data on both naïve and switched patients [16] [17] [18] [19] [20] [21] [22] [23] , four of which reported the efficacy data stratified for naïve and non-naïve patients [17] [18] [19] [20] .
Disease activity was assessed by the Crohn's Disease Activity Index (CDAI) [26] (in seven studies out of 11) and by the partial Mayo Scoring System or the Mayo Scoring System (MSS) in patients with CD or UC, respectively [27, 28] . Disease activity was estimated at the start and after the induction therapy. CD response was defined as a \150-point or no fistula drainage, as assessed by the Fistula Drainage Assessment. UC response was defined as a [30% decrease in the activity index and a decrease in the rectal bleeding and endoscopy subscores. One study on pediatric patients with IBD assessed disease activity using the Pediatric Crohn's Disease Index (PCDAI) [29, 30] and Pediatric Ulcerative Colitis Activity Index (PUCAI) [31] . Three studies out of 11 assessed disease activity by the Harvey-Bradshaw Index in CD [32] . One study out of 11 assessed efficacy using the Simple Clinical Colitis Activity Index (SCCAI) for UC [33] . One study focused on the mucosal healing of patients suffering from UC and assessed the efficacy by defining the mucosal healing as having a Mayo endoscopic subscore of 0 or 1; complete mucosal healing was defined as a Mayo endoscopic subscore of 0 [34] . Three studies out of 11 included C-reactive protein (CRP) and fecal calprotectin [15, 23, 25] as markers of inflammation; six of 11 studies included CRP alone [16, 18, 19, 21, 22, 24] . The protocol of infusion for seven of 11 studies was 5-mg/kg intravenous infusions of CT-P13 at week 0, 2 and 6, followed by a maintenance regimen every 8 weeks. In one study, CT-P13 was infused at week 0, 2, 6 and 14, and in two studies the infusion protocol was not specified, but CT-P13 was infused at the standard doses. In one of those studies, efficacy was assessed after at least one infusion of CT-P13, while the other study reported that 78 of 83 patients completed follow-up and received three or more CT-P13 infusions. One study reported that 49% of patients received infusions at 8-week intervals and 66% of patients received doses of 4-6 mg/kg. The individual dose varied between 200 and 900 mg, and the intervals for administration varied between 4 and 12 weeks [25] .
Overall, no significant difference in efficacy between the originator infliximab and its biosimilar CT-P13 was observed. Four out of 11 studies reported the data of switched patients separately from that of naïve patients, and three of the four studies did not show a significant difference between the two groups, with the exception of switched patients who had already developed anti-drug antibodies (ADA) against the originator infliximab or, in some cases, adalimumab. On the contrary, one study reported a significant difference between the two groups, pointing out a better response in the naïve group compared with the switch group.
Safety
Nine-hundred forty-four patients with IBD from ten studies were eligible for this analysis, including 570 patients with CD (294 switched and 276 naïve), 372 with UC (122 switched and 250 naïve) and two IBD unclassified patients (switched). Data regarding treatment adverse events (TEAEs) are summarized in Table 2 . Adverse events analysis included infusion-related reactions, infections, malignancies and death.
Studies differed in their definition of TEAEs. One study classified TEAEs as mild, moderate and severe according No study reported a significant difference between the originator infliximab and its biosimilar CT-P13 regarding the safety analysis. When separating naïve and non-naive patients (in six studies [15, [17] [18] [19] [20] 23] ), no significant difference between the two groups was observed. However, a detailed analyses was possible in a limited number of the studies [15, 17, 18] ; only three studies reported the data of switched patients separately from that of patients naïve to treatment, and one study differentiated the results between the two groups only when analyzing the infusionrelated reactions. In detail, three of the eight studies analyzing results from both naïve and switched patients reported the data separately. Infusion-related reactions occurred in 39 of 944 patients (4.1%), including two anaphylactic reactions (0.2%) [17, 19] . Infections occurred in 41 of 944 patients (4.3%), including one patient who experienced a fatal invasive fungal infection [19] , and one tuberculosis infection (0.1%) [17] . One patient developed a lymphoma and stopped treatment because of the adverse event (0.1%) [25] . No serum sickness-like syndrome, no solid malignancies, no drug-induced lupus and no demyelization syndrome were reported in the analyzed data.
Immunogenicity Analysis
Six hundred and sixteen IBD patients from 6 studies were eligible for this analysis, including 346 patients with CD (182 switched and 164 naïve), 268 with UC (99 switched and 169 naïve) and 2 IBD unclassified patients (switched). Data regarding the immunogenicity analysis is summarized in Table 3 .
Studies were analyzed for titers of anti-drug positivity both for naïve patients and for patients who switched from originator infliximab. Drug level monitoring was also taken into consideration when reported.
Two studies reported data only for switched patients, and four of the six studies analyzed both naïve and switched patients. ADA level prior to the treatment with CT-P13 was assessed only in two of the six studies. One study reported ADA positivity in the switched group of 25% compared with 4% in the naïve group, whereas, the other study reported data only for switched patients.
All six studies assessed ADA levels after therapy with CT-P13, and all studies showed no significant difference in terms of immunogenicity between the originator infliximab and its biosimilar CT-P13. Four out of six studies reported a higher, but not significant, incidence of ADA positivity in the switched group compared with the naïve patients, especially in the patients who had previously developed ADA against the originator infliximab. One study [19] reported a significant difference between the naïve and switched groups, reporting a higher incidence of ADA positivity in the switched group. ADA anti-drug antibodies, CD Crohn's disease, IBD inflammatory bowel disease, IFX infliximab, IFX/ADA anti-drug antibodies against originator infliximab, N/A not applicable, TNF tumor necrosis factor, UC ulcerative colitis a Suspected infusion-related reactions occurred in 6/83 patients (7%): 2 pruritus, 2 dizziness, 1 warm sensation, 1 patient developed progressive arthralgia after the second infusion b 10 patients experiencing infusion reaction of any severity had previously received the originator infliximab c After change to the originator, arthralgia did not recur
Discussion
In our analysis considering 1007 patients with IBD, including 570 patients with CD (48% naïve) and 435 with UC (71% naïve), we observed a similar efficacy profile in patients treated with CT-P13 when compared to studies including patients who received originators [6, 35, 36] . Similarly, when assessing the safety of CT-P13, we found that 9.2% of the patients experienced adverse effects (4.1% infusion-related reactions and 4.3% infections), and this incidence is comparable to that observed in randomized controlled trials with originator anti-TNF [37] . In fact, [7] . Interestingly, no patients treated with CT-P13 included in our analysis developed serum sickness-like syndrome, drug-induced lupus or demyelization syndrome during the observation time.
Our results are in line with the findings of the recent extension studies of both PLANETRA and PLANETAS; when following-up the same cohorts of patients over the course of 2 years, they analysed the equivalence to originator infliximab in AR and AS patients, respectively [38, 39] . Over 2 years of treatment, comparable results between groups of patients (patients treated with originator infliximab and with the biosimilar CT-P13) regarding efficacy, tolerability and immunogenicity were observed in patients who switched from infliximab to its biosimilar for an additional year (for the PLANETAS study) and in those who had long-term CT-P13 treatment for 2 years.
The extended results of these two studies are very promising; however, they represent the sole trials in which the biosimilar equivalence was tested, demonstrated in two specific cohorts of patients. When extrapolating a drug for other indications, the selection of the patient population is crucial. Better results are shown when a high difference in efficacy between a test drug and placebo is present. RA for infliximab, one of six of its indications, revealed the smallest placebo-adjusted response, making the population of patients suffering from RA a less sensible model to demonstrate a possible difference in the bioequivalence of CT-P13 and its originator infliximab [40] .
Regarding immunogenicity, we found that all six studies assessing ADA levels after therapy with CT-P13 showed no significant difference in terms of immunogenicity between the originator infliximab and its biosimilar CT-P13. Immunogenicity profiles between various patient populations should be a matter of focus when extrapolation of indication is considered. Indeed, given the CD population has shown the highest incidence of immunogenicity (up to 61%) [41] and the lowest was demonstrated in the RA population (less than 10%) [42] , further studies addressing differences in immunogenicity profiles in patients with different diseases are warranted.
Similarly, the issue of switching from a reference product to its biosimilar is still being debated. The PLANETAS study has shown promising results after 1 year of treatment in patients who switched to CT-P13 from its originator; similar results were described by Ruiz-Argüello et al. [43] , which showed identical reactivity towards biosimilars in a cohort of patients with rheumatic diseases treated with infliximab. However, the concerns around immunogenicity in switched patients might represent an unsolved problem, as we found a significant difference between the naïve and switched groups, with a higher incidence of ADA positivity in the switched group [19] . However, more data are needed to confirm this observation.
Limitations of the Study
The present systematic review has several limitations. In fact, most of the analyzed studies have a retrospective design; therefore, some caution should be taken when interpreting results. Furthermore, the present systematic review is based on uncontrolled studies, as no randomized controlled studies to date have evaluated the treatment of IBD with CT-P13 in comparison with its originator infliximab. Additionally, the results were, in some cases, heterogeneous due to the use of different classifications, methods and criteria for assessing efficacy, safety and immunogenicity. Moreover, the follow-up time of the studies was relatively short; long-term consequences should be evaluated with studies with a longer follow-up.
We cannot exclude the possibility that some patients were included in both Farkas et al.'s two studies [16, 21] and the study by Gecse et al. [19] , as this issue was not clearly detailed in the manuscripts. Furthermore, due to the intrinsic limitation of the studies (different number of patients included, heterogeneity in terms of protocol and study design), the risk of bias in individual studies could not be assessed.
Future Challenges
Biosimilars of biological drugs are raising interest in the scientific community, and new forms of biosimilars are either under development, being tested for regulatory approval or are awaiting extrapolation approval. Currently, physicians are facing the challenge of choosing between a biological drug and its biosimilar and switching from an originator to its biosimilar. In the future, physicians might also have to decide whether to switch back to the originator from its biosimilar (reverse switch) or to switch to a different biosimilar drug (cross switch). Further efforts are underway to develop new classes of biosimilars, such as the so called 'bio-betters,' which have the objective of rising above their originators in terms of their clinical profile, through alteration of their chemical composition and formulation [44] .
However, the necessity and challenge of further standardization of international guidelines and regulatory legislation still exist. Prospective randomized phase III trials are needed in order to ensure the efficacy and safety of biosimilars, as well as their interchangeability. An ongoing study, NOR-SWITCH, a randomized, double-blind, parallel-group, non-inferiority study, aims to assess the safety and efficacy of switching from infliximab to the biosimilar treatment in patients with RA, spondyloarthritis, PsA, UC, CD and chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT02148640). Furthermore, an ongoing phase III study is currently aiming to assess non-inferiority in efficacy and the overall safety of CT-P13 compared with infliximab in patients with active CD up to week 54 (ClinicalTrials.-gov identifier: NCT02096861).
Conclusion
Despite no trials addressing the use of CT-P13 in IBD in a randomized fashion, the current literature, including observational studies about the clinical experience of CT-P13, is promising. The analyzed studies did not report a significant difference in terms of efficacy, safety and immunogenicity when comparing the clinical experience with CT-P13 with the available literature data on originator treatment in IBD. However, some debate is ongoing regarding interchangeability and immunogenicity.
